Related Experiment Video
Updated: May 12, 2026
07:55
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
CD40 immunotherapy for pancreatic cancer
Robert H Vonderheide1, David L Bajor, Rafael Winograd
1Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104-5156, USA. rhv@exchange.upenn.edu
Cancer Immunology, Immunotherapy : CII
|April 17, 2013
Summary
Targeting the CD40 pathway shows promise for pancreatic cancer immunotherapy. CD40 agonists activate immune cells and modify the tumor microenvironment, leading to tumor regression in both mice and patients.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDA) is an aggressive cancer with poor response to conventional treatments.
- The PDA tumor microenvironment is highly immunosuppressive, limiting the efficacy of current therapies.
- Emerging research suggests immunotherapy, particularly targeting the CD40 pathway, holds potential for PDA treatment.
Purpose of the Study:
- To investigate the therapeutic potential of targeting the CD40 pathway in pancreatic ductal adenocarcinoma.
- To evaluate both laboratory and clinical efficacy of CD40 agonists in PDA immunotherapy.
- To elucidate the immune mechanisms underlying CD40-mediated tumor regression in PDA.
Main Methods:
- Utilized genetically engineered and other mouse models of PDA.
- Conducted laboratory studies and clinical trials involving CD40 agonists.
- Analyzed immune responses, including T-cell-dependent and T-cell-independent mechanisms.
Main Results:
- CD40 agonists demonstrated efficacy in mediating tumor regression in both preclinical models and human patients.
- Observed both T-cell-dependent and T-cell-independent immune mechanisms contributing to tumor destruction.
- T-cell-independent mechanisms involved macrophage activation and degradation of the PDA tumor stroma.
Conclusions:
- Targeting the CD40 pathway represents a promising immunotherapeutic strategy for pancreatic ductal adenocarcinoma.
- Immune modulation of the tumor microenvironment via CD40 agonists can overcome PDA's resistance to therapy.
- CD40-targeted immunotherapy offers a novel approach to enhance treatment outcomes for pancreatic cancer patients.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...